What is the recommended treatment plan for gastrointestinal manifestations such as constipation, dysmotility, reflux, and small‑intestinal bacterial overgrowth in patients with Ehlers‑Danlos syndrome?

Treatment of Gastrointestinal Issues in Ehlers-Danlos Syndrome

Treat GI symptoms in Ehlers-Danlos syndrome by targeting the most prominent symptoms with standard DGBI therapies, while simultaneously addressing comorbid POTS and MCAS when present, using a symptom-focused approach that includes dietary modifications, prokinetics for dysmotility, histamine antagonists for MCAS, and increased fluid/salt intake for POTS. 1

Core Treatment Strategy

The 2025 AGA guidelines provide the most current framework for managing GI manifestations in hypermobile EDS (hEDS). The approach centers on treating predominant symptoms and abnormal GI function test results, rather than attempting to address the underlying connective tissue disorder itself 1.

Primary Symptom Management

For upper GI symptoms (nausea, vomiting, reflux):

• Antiemetics: ondansetron, promethazine, prochlorperazine, or aprepitant
• Prokinetics: metoclopramide, domperidone, erythromycin, or prucalopride for documented gastroparesis
• Acid suppression: proton pump inhibitors or H2 receptor antagonists for reflux symptoms 1

For abdominal pain:

• Antispasmodics (hyoscyamine) for cramping
• Avoid opioids due to risk of worsening dysmotility and dependency 1

For constipation and pelvic floor dysfunction:

• Standard laxatives and stool softeners
• Consider anorectal manometry testing, as rectal hyposensitivity and pelvic floor dysfunction are highly prevalent in this population 1
• Pelvic floor physical therapy when defecation disorders are confirmed

Treating Comorbid POTS (Postural Orthostatic Tachycardia Syndrome)

Approximately 37% of hEDS patients with GI symptoms have POTS 2, which directly impacts GI function. Treatment includes:

• First-line conservative measures: Increase fluid intake (2-3 liters daily) and salt intake (6-10 grams daily), exercise training, compression garments 1
• Pharmacological therapy for non-responders: volume expanders, heart rate control agents, vasoconstrictors—requires cardiology or neurology consultation 1

Treating Comorbid MCAS (Mast Cell Activation Syndrome)

When MCAS is suspected (episodic multisystem symptoms including GI, skin, cardiac, respiratory):

Diagnostic approach:

• Obtain baseline serum tryptase and repeat 1-4 hours after symptom flares
• A 20% increase above baseline plus 2 ng/mL confirms mast cell activation 1
• Refer to allergy specialist or mast cell disease center for additional testing if positive 1

Treatment:

• Histamine receptor antagonists (H1 and H2 blockers)
• Mast cell stabilizers (cromolyn sodium)
• Trigger avoidance: specific foods, alcohol, strong smells, temperature changes, mechanical stimuli, emotional stress, certain medications (opioids, NSAIDs, iodinated contrast) 1

Dietary Interventions

Specialized diets can improve symptoms but require nutritional counseling to avoid restrictive eating pitfalls 1:

• Gastroparesis diet (small particle, low-fat diet) for documented delayed gastric emptying
• Low FODMAP diet for bloating and IBS-like symptoms
• Gluten-free or dairy-free diets if specific intolerances identified
• Low-histamine diet when MCAS is present
• Nutritional support: liquid formulas or enteral feeding for severe cases 3

Small Intestinal Bacterial Overgrowth (SIBO)

SIBO is common in EDS due to dysmotility 3, 4. While the 2025 guidelines don't specifically address SIBO testing in routine evaluation 1, consider it when:

• Bloating, gas, and diarrhea are prominent
• Symptoms persist despite standard DGBI treatment

Treatment:

• Rifaximin (nonsystemic antibiotic, well-tolerated) 5
• Alternative: norfloxacin, metronidazole, or broad-spectrum penicillins with anaerobic coverage 5, 6
• May require repeated courses 6

Diagnostic Testing Priorities

Before initiating treatment, consider:

1. Celiac disease testing early in evaluation—not just for diarrhea but for varied GI symptoms 1
2. Gastric emptying studies in patients with chronic upper GI symptoms and comorbid POTS, as abnormal emptying is more common than in general population 1
3. Anorectal manometry for constipation with incomplete evacuation 1
4. Avoid routine testing for disaccharidase deficiencies without specific indication 1

Critical Pitfalls to Avoid

• Do not use opioids for pain management—they worsen dysmotility and create dependency 1
• Avoid overly restrictive diets without nutritional guidance—can lead to malnutrition and disordered eating (ED history is more common in EDS patients) 7
• Do not over-test for MCAS in all hEDS patients—only pursue when episodic multisystem symptoms suggest generalized mast cell disorder 1
• Recognize that 98% of hEDS patients meet criteria for DGBI—use positive symptom-based diagnosis rather than extensive testing 1

Multidisciplinary Care Requirements

Given the multisystemic nature of hEDS, coordinate care with:

• Cardiology/neurology for POTS management
• Allergy/immunology for MCAS
• Nutrition for dietary interventions
• Psychology for brain-gut behavioral therapies (anxiety and psychological distress are increased in this population) 1
• Physical therapy for pelvic floor dysfunction

The evidence base for EDS-specific GI treatments remains limited 1, 8, so management largely follows standard DGBI principles while addressing the unique comorbidities that amplify symptoms in this population.